Archive

Tiara and Reducer Featured at CSI Frankfurt 2018

NASDAQ, TSX: NVCN VANCOUVER, July 2, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TZX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that its Tiara™ ("Tiara"), a transcatheter treatment of mitral valve disease, and the...

Read More

Tiara™ Featured in Live Case at 11th Annual TVT 2018

NASDAQ, TSX: NVCN VANCOUVER, June 21, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that its Tiara™ ("Tiara") transcatheter mitral valve replacement device was featured in a...

Read More

Neovasc Announces First Implant of a Neovasc Reducer™ in a U.S. Patient

NASDAQ, TSX: NVCN VANCOUVER, June 20, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced the first U.S. patient has been implanted with a Neovasc Reducer™ (the "Reducer"),...

Read More